Back
Full-text
Journal article

Telmisartan: a different angiotensin II receptor blocker protecting a different population?

  • Burnier M Division of Nephrology and Hypertension Consultation, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Michel.Burnier@chuv.ch <Michel.Burnier@chuv.ch>
  • 2010-02-12
Published in:
  • The Journal of international medical research. - 2009
Angiotensin II Type 1 Receptor Blockers
Benzimidazoles
Benzoates
Endothelium, Vascular
Humans
Hypertension
PPAR gamma
Population Groups
Telmisartan
English The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET()) showed that the angiotensin II receptor blocker (ARB) telmisartan was as protective as the reference-standard ramipril in a broad cross-section of patients at increased cardiovascular risk, but was better tolerated. Telmisartan has a unique profile among ARBs, with a high affinity for the angiotensin II type 1 receptor, a long duration of receptor binding, a high lipophilicity and a long plasma half life. This leads to sustained and powerful blood pressure lowering when compared with the first marketed ARBs, such as losartan and valsartan. Some pharmacological properties of telmisartan clearly distinguish it from other members of the ARB class and may contribute to the clinical effects seen with telmisartan. A class effect for ARBs cannot be assumed. To date, telmisartan is the only ARB that has been shown to reduce cardiovascular risk in at-risk cardiovascular patients.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/86332
Statistics
Document views: 22 File downloads:
  • fulltext.pdf: 0